On the whole, the reported findings indicate that EGFR nuclear localization is a negative prognostic factor in HNSCC and suggest that it may be regarded as a biomarker for clinical resistance as well as a potential therapeutic target (95). The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.